Скачать или смотреть Helping to Address Unmet Needs in Metastatic HR+/HER2- Breast Cancer

Despite significant treatment advances for HR+/HER2- metastatic breast cancer, the five-year relative survival rate is only 30%. There’s an urgent need for new treatment options, and Gilead Oncology’s vision is to help bring more life to people with this disease.

For more information about Gilead, visit:
Website: https://www.gilead.com
Stories@Gilead: https://stories.gilead.com
Twitter:   / gileadsciences  
LinkedIn:   / gileadsc.  .
Instagram:   / gileadsciences  
Facebook:   / gileadsciences  

About Gilead
At Gilead, we’re committed to creating a healthier world for everyone – no matter the challenges ahead of us. For more than 35 years, we’ve pursued the impossible, chased it down, tackled it for answers and surrounded it for a way in. We have worked tirelessly to bring forward medicines for life-threatening diseases.

Through bold and transformative science, we’re driving innovation that has the potential to become the next generation of life-changing medicines. Our ambition is evident in our mission. Because the impossible is not impossible. It’s what’s next.